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The conflicts in Iraq and Afghanistan have placed an increased awareness on traumatic
brain injury (TBI). Various publications have estimated the incidence ofTBI for our deployed
servicemen, however all have been based on extrapolations of data sets or subjective eval-
uations due to our current method of diagnosing aTBI.Therefore it has been difficult to get
an accurate rate and severity of deployment relatedTBIs, or the incidence of multipleTBIs
our service members are experiencing. As such, there is a critical need to develop a rapid
objective method to diagnose TBI on the battlefield. Because of the austere environment
of the combat theater the ideal diagnostic platform faces numerous logistical constraints
not encountered in civilian trauma centers. Consequently, a simple blood test to diagnosis
TBI represents a viable option for the military. This perspective will provide information on
some of the current options for TBI biomarkers, detail concerning battlefield constraints,
and a possible acquisition strategy for the military.The end result is a non-invasiveTBI diag-
nostic platform capable of providing much needed advances in objective triage capabilities
and improved clinical management of in-Theater TBI.
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THE TBI PROBLEM
In the early years of the wars in Afghanistan (Operation Enduring
Freedom, OEF) and Iraq (Operation Iraqi Freedom, OIF), there
appeared to be an increase in the numbers of causalities sustaining
a traumatic brain injury (TBI). By early 2005 TBI was being called
the “signature wound of war in Iraq” as cases of soldiers suffering
from TBI were appearing in National newspapers, such as USA
Today (Okie, 2005; Zoroya, 2005). The increased awareness and
emphasis of TBI in the military population spurned a movement
to identify and collect data on the incidence of TBI in our deployed
forces.
The incidence of TBI in the deployed forces varies depending
upon the type of information collected. One initial study examined
a cohort of casualties that were wounded in OEF/OIF from 2001
to 2005. The study reported that approximately 30% of wounds
were to the head and neck area with 8% of the total attributed
as head wounds (Owens et al., 2008). However, this study was
based on casualties treated for wounds, and excluded those that
were returned to duty within 72 h, thus potentially missing TBI
cases that were mild and did not accompany an open wound. The
RAND Corporation’s “Invisible Wounds of War” collected data
from April 2007 to January 2008, part of which included a tele-
phone survey of 1,965 previously deployed persons. From this
survey they reported that 19.5% of the previously deployed per-
sons suffered from a“probable TBI.”They further estimated that of
the 1.64 million deployed service members (at that time), 19.5% of
them, or 320,000 have suffered a TBI (Tanielian and Jaycox, 2008).
However, data collected from the Armed Forces Health Surveil-
lance Center show that by the end of 2008 there had only been
approximately 130,000 clinically confirmed cases of TBI. In addi-
tion, the number of TBI diagnosis rose sharply between the years
of 2005 thru 2009, specifically in the cases of mild TBI (mTBI;
http://www.health.mil/Research/TBI_Numbers.aspx). Is this rise
in TBI a real rise, or an increase in TBI awareness and improved
vigilance for detecting TBI? Clearly there appears to be a real chal-
lenge on getting an accurate estimate of the actual incidence of
TBI experienced by our deployed Forces.
DIAGNOSING TBI
One of the issues creating this challenge lies in the current lim-
itations in the diagnosis of TBI, specifically for the military. In
general, the diagnosis of TBI relies on a clinician to accurately
interpret a patient’s signs and symptoms of injury, often through
some type of self-report from the patient and possibly corrob-
orated by a witness. In the case of a penetrating brain injury,
the signs and symptoms are more straightforward. However, with
closed-head injuries, especially mTBIs/concussions, the symptoms
are often not as straightforward or clear. Typically the initial eval-
uation of a possible TBI captures the patients Glasgow Coma Scale
(GCS), the length of loss of consciousness, alteration of conscious-
ness/mental state, and/or post-traumatic amnesia (Harrington
et al., 1993; Meyer et al., 2010). If certain symptoms are present the
clinician can further evaluate the injury by image analysis of the
brain via a computed tomography (CT) scan or even magnetic res-
onance imaging (MRI), both of which have their own limitations
in the ability to detect TBI, especially mTBI (Chastain et al., 2009;
Mondello et al., 2011a; Prabhu, 2011). Besides the image analysis,
most of the tools to aid in the diagnosis of TBI are subjective and
as stated above involve self-reporting. Hence, there are no true
objective measures available to determine that the brain indeed
has been injured, thus the ability to diagnose closed-head TBI,
especially those of the mild-moderate severity, is at best limited by
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available methods. However, the ability to diagnosis a TBI can also
be limited by the setting.
The civilian environment and the military (deployed) envi-
ronment are vastly different. In a civilian setting, if someone
experiences a head injury from a motor vehicle accident, fall, or a
sporting event, the event is often witnessed; they are quickly trans-
ported to the local medical facility and promptly evaluated by a
medical professional, sometimes with access to the latest imaging
technology. In the military setting, there is often some type of battle
taking place either before, during, or after, when someone experi-
ences a head injury. By its very nature the event is dangerous, and
often chaotic and loud, occurring in remote locations and possibly
lasting hours before casualties can be evaluated by a clinician. In
addition, the military casualty can and often will experience mul-
tiple serious injuries (Kelly et al., 2008; Owens et al., 2008) and the
evaluation of a potential head injury can take a back seat to life
saving interventions, possibly missing the treatment window for
the TBI. Further, evacuation priorities and logistics may impact
the ability to evaluate all suspected mTBI cases to the same extent
as a civilian setting as the ability to image the brain is only located
at specific locations in the theater of operations. Clearly the mil-
itary setting creates another layer of difficulty and complexity in
the ability to diagnose TBI.
ON THE BATTLEFIELD
Due to the complexities of war and of TBI, it has been extremely
difficult to get a handle on the rate of TBIs experienced during a
deployment, not to mention the severity of TBIs or the incidence
of multiple TBIs our service members are actually experiencing, or
not experiencing. One of the major reasons is the lack of a method
to objectively determine if the brain has been injured. In 2006 the
Military Acute Concussion Evaluation (MACE) was add to the list
of tools to screen casualties (Meyer et al., 2010). While the MACE
has been well integrated into the military medical evaluation, it
still relies on subjective recall of the events, may be affected by
fatigue as other neuropsychological tests and has shown low sensi-
tivity when administered greater than 12 h (Coldren et al., 2010).
Thus there remains a gap for the ability to objectively measure
brain injury with a method that is not impacted by other factors
such as extra-cranial injury (i.e., polytrauma), stress, fatigue, or
battlefield conditions.
Due to the logistic constraints faced on a battle field, any
method involving a piece of equipment, must meet additional
requirements sometimes not faced in civilian medical care. The
battlefield is often a very austere environment. The most restric-
tive environments are often isolated locations where power supply
is lacking or being provided by a generator which must sustain
all of the electrical needs for the deployed force. Since units often
need to remain quickly mobile, the footprint of the unit is limited,
so space, and weight of equipment is a priority concern. In addi-
tion, if medical refrigeration exists, it is typically small and in high
demand and there is little hope of having specialized reagents such
as deionized water. Further consideration is given to the shelf-life
of a piece of equipment and its ability to sustain high altitude,
large temperature, and/or humidity fluctuations and a consider-
ably dusty and dirty environment. Taking all of these issues into
consideration, the ideal method for the diagnosis of TBI would be
quick, simple, easy to obtain, not rely on self-report of symptoms,
and be portable. In addition, the results of the test should be able
to differentiate the severity of injury and in a most ideal world, be
predictive of some level of clinical outcome.
OBJECTIVE DIAGNOSTIC TEST FOR TBI
In recent years there have been a number of technologies under
development to objectively aid in the diagnosis of TBI (Marion
et al., 2011). Some of these include advances in MRI (Kumar et al.,
2010; Prabhu, 2011), quantitative electroencephalogram (EEG;
Nuwer et al., 2005), visual tracking (Maruta et al., 2010), and
serum based biomarkers of brain injury (Dash et al., 2010). Using
the logistical constraints mentioned above and the need for the test
to not be confounded by conditions of deployment (sleep depriva-
tion, stress, fatigue, etc.), one of the more promising options is the
development of a simple blood test to detect brain specific proteins
after a TBI. Blood based tests have been successful in the diagnosis
of other disease conditions such as cardiac disease and cancer, so
it is possible biomarkers could be identified for TBI as well.
The TBI community has been actively engaged in the discov-
ery of biomarkers for TBI in the last decade. A number of review
articles have captured the pros and cons of various potential mark-
ers (Dash et al., 2010; Mondello et al., 2011a). Some of the more
promising candidates have been tested in human clinical trials of
TBI patients, most of them in severe TBI (Hergenroeder et al.,
2010; Liliang et al., 2010; Mondello et al., 2010, 2011b, 2012a,b;
Vos et al., 2010; Brophy et al., 2011; Stein et al., 2011, 2012; Gong
et al., 2012). A number of proteins of interest are markers that are
not solely found in the brain (i.e., cytokines, growth factors, inter-
leukins; Hergenroeder et al., 2010; Stein et al., 2011; Gong et al.,
2012). While these may provide clinical utility in situations of head
trauma with no confounding injuries, this is typically not the case
in the military combat causality. However, a number of markers
of interest are more brain specific, to include S100B, glial fibrillary
acidic protein (GFAP), Ubiquitin C-terminal hydrolase L1 (UCH-
L1), Neuron Specific Enolase (NSE), spectrin breakdown products
(SBDP), and Tau (Siman et al., 2009; Liliang et al., 2010; Mondello
et al., 2010, 2011b, 2012a,b; Vos et al., 2010; Brophy et al., 2011;
Stein et al., 2012).
Most of the clinical trials have been conducted with severe
TBI patients, but a few have also included moderate and mTBI
patients as well and show promise (Honda et al., 2010; Papa et al.,
2012a,b; Topolovec-Vranic et al., 2011; Egea-Guerrero et al., 2012).
In an early study of S100B in mTBI subjects, S100B serum levels
were significantly different between mTBI patients and uninjured
controls (Nygren De Boussard et al., 2004). However, S100B is
also increased in other extra-cranial injuries, making less than
ideal in the military environment (Savola et al., 2004). Promis-
ing recent studies include a study on moderate-mTBI (GCS≤ 12),
that demonstrated that the levels of GFAP in patient serum were
able to significantly differentiate not only between TBI patients
and uninjured controls, but also between TBI patients and trauma
controls (trauma injury without head injury). Further, when TBI
groups were dichotomized into traditional groups of mTBI (GCS
13–15) and moderate TBI (GCS 9–12), the level of serum GFAP
were significantly different between groups (Papa et al., 2012a).
Similar results were demonstrated with serum levels of UCH-L1
differentiating between mTBI, moderate TBI, normal, and trauma
controls (Papa et al., 2012b). Another study recently characterized
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the differences in areas under the curve (AUC) for sensitivity and
specificity of GFAP, S100B, and NSE in TBI patients (GCS range
5–14) determined by positive CT findings. GFAP performed the
best with sensitivity set to 100% and the corresponding specificity
was 88.9% on day one compared to S100B with a specificity of
27.8% and NSE with a specificity of 22.2% on day one (Honda
et al., 2010).
TBI BIOMARKER PLATFORMS FOR THE FIELD
Although recent trials have indicated that it is possible to detect
TBI biomarkers in the serum of injured patients, all of the studies
have taken place in civilian centers and were able to use a research
laboratory platform for analysis. Typically this platform is a stan-
dard enzyme-linked immunosorbent assay (ELISA) which has a
number of limitations for use in a combat environment. First, the
typical assay requires multiple pieces of equipment (reader, incu-
bator, and automated washing machine), refrigeration of reagents,
and deionized water. Second, the assay can be lengthy to run, tak-
ing as little as 4 h and as many as 24 h. Third, the standard assay
plate consists of 96 wells, which could equate to wasting two-thirds
of a plate if there is only one sample to assay. However, when we
consider the needs for our military applications the assay in an
ELISA platform is indeed the most mature in development and
testing of clinical samples. Similarly this platform could poten-
tially have greater sensitivity (lower limits of detection) and serve
as a benchtop in a reference laboratory. In addition, porting the
standard ELISA assay onto an automated benchtop platform could
cut down on some of the size and weight of the system.
On the other end of the spectrum would be the development
of a hand-held device that performs similar to a TBI “pregnancy
test.” Such hand-held systems would be lightweight, portable, and
require little logistical support. The assay time and waste would
likely be reduced as well. However, these devices do not exist
today for the TBI biomarkers that have been examined in clin-
ical studies; therefore they are the least mature in development
and Food and Drug Administration (FDA) approval timeline. In
addition, it is possible that this platform could suffer in the limit
of detection.
As mentioned above, the development of a device platform for
the military environment presents unique challenges with differ-
ent restrictions upon instrumentation at each level of care. The
initial level of combat casualty care is located close to the point of
injury such as a Battalion Aid Station (BAS). This level of care is the
most remote and has the highest logistical constraints concerning
power, refrigeration, and footprint. In addition, this level of care
does not have much capacity, if any, to hold patients for treatment
and evaluation. The most robust level of care on the battlefield
is located at a combat support hospital (CSH) or a field hospital.
It includes specialist diagnostic resources, specialist surgical and
medical capabilities, and operational stress management teams.
The holding capacity is sufficient to allow diagnosis, treatment,
and holding of those patients who can receive total treatment and
be returned to duty. However, it is still a deployed environment
faced with the same challenges of reduced and restricted foot-
print, especially for power and refrigeration. For the highest level
of definitive care, patients are evacuated back to fixed facility hos-
pitals such as Landstuhl Regional Medical Center or Walter Reed
National Military Medical Center. These hospitals operate as any
civilian medical facility with few, if any, logistical constraints.
MILITARY ACQUISITION APPROACH
Given (1) the importance of providing an objective test to aid in
the diagnose of TBI, (2) the level of maturity of platforms to eval-
uate TBI biomarkers, and (3) the unique abilities and constraints
on each level of possible medical care, the best approach to solve
this problem may be an phased acquisition approach (Mondello
et al., 2011a; Figure 1). The first phase of development/fielding
should focus on the technology that is the most mature, and poten-
tially fieldable, not only in terms of platform logistics but also in
clinical testing and familiarity with the FDA. Therefore, Phase I
could focus on an automated benchtop system suitable for use in
a fixed medical facility. Although this system is the most complex
and logistically intensive, it is the most similar to the standard
research ELISA that have been employed in previous testing of
clinical samples. In addition, it could possibly have the highest
level of sensitivity for detection of biomarkers and ultimately serve
as a reference platform for confirmatory testing (higher diagnos-
tic specificity). Phase II could be a small single assay point-of-care
system, such as a physician’s office or a field hospital. Phase II sys-
tems would ideally have the ability to screen for the presence of
mild-moderate TBI and differentiate the level of severity for all
TBIs. Ideally Phase II systems would be more portable than Phase
I systems, have the availability of battery operation and require less
refrigeration of reagents. Phase III systems could be a miniatur-
ized hand-held system, most suitable for use by emergency medical
personnel or personnel deployed in the remote and more austere
locations on the battlefield, such as a BAS. These systems would
ideally use whole blood from a finger stick to screen for the pres-
ence of TBI. They would use little power supply and require no
refrigeration. Currently, Phase III systems are the least mature
in development and testing for TBI biomarkers, but would pro-
vide the most use for screening of casualties (highest diagnostic
sensitivity).
If all three Phases of systems were developed and deployed, one
could image a scenario that starts with screening casualties for the
presence of TBI biomarkers immediately after an event. Screening
tests can typically have higher diagnostic sensitivity than diag-
nostic specificity (Ruan et al., 2009; i.e., more false positives than
false negatives). Using a screening test designed in this manner will
ensure you do not miss a casualty with a possible TBI, however you
will have more people identified as having a TBI that could later be
ruled out. The casualty could be evacuated back to the next higher
level of care that can provide a more robust confirmatory test for
the TBI biomarkers. At the highest level of care, the test could be
more confirmatory and have a higher diagnostic specificity than
sensitivity (lower number of false positive) and essentially rule in
those with TBI and determine which casualties were false posi-
tives for the screening test. In addition, TBI biomarker assays at
the highest level of care could also be used to possibly determine
what type of injury has occurred and monitor if the injury is get-
ting worse over time or better with treatment (Mondello et al.,
2011a). This scenario also fits well with the current military lev-
els of medical care on the battlefield. The biomarker assay screen
(Phase I/II) could be completed during the initial assessment after
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FIGURE 1 | Potential placement ofTBI diagnostic assay systems. Each
potential device has advantages and disadvantages that constrain its use
in the military medical system. Solid lines represent ideal placement of
each system, dashed lines represent possible placement of each system
depending on logistical support. All device pictures are representative
examples of commercially available devices, but do not indicate the use of
TBI biomarkers on each device. Pictured benchtop device is Dynex
Technologies DS2™and DSX™(http://www.dynextechnologies.com),
pictured point-of-care device is Abbott Laboratories ISTAT®
(http://www.abbottpointofcare.com).
injury, where the other screening test, the MACE is performed. The
biomarker assay confirmatory test (Phase III) could be performed
at a field hospital where other more extensive diagnostic tools are
available, such as a CT.
SUMMARY
Overall the current methods to diagnosis a TBI could be improved
with the development and addition of a non-invasive, objec-
tive test for the presence of TBI. Current research and develop-
ment in the field of biomarkers give hope the development of
such an objective diagnostic test. However, military conditions
contain logistical constraints which may require different plat-
forms for different levels of care. Development of this non-invasive
TBI diagnostic platform applicable to all levels of military care
would provide much needed advances in objective triage capa-
bilities and improved clinical management of in-Theater TBI.
The ability to objectively determine the occurrence of an ini-
tial mTBI/concussion and the incidence of multiple mTBIs on
our front lines of defense is critical to the success of our military
operations, and to the long term health of our warfighters. Like-
wise, improved TBI diagnosis will also significantly advance the
management of civilian patients.
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